USRE34136E - 9 alpha, 11 beta-substituted and 11 beta-substituted estranes - Google Patents

9 alpha, 11 beta-substituted and 11 beta-substituted estranes Download PDF

Info

Publication number
USRE34136E
USRE34136E US07/434,849 US43484989A USRE34136E US RE34136 E USRE34136 E US RE34136E US 43484989 A US43484989 A US 43484989A US RE34136 E USRE34136 E US RE34136E
Authority
US
United States
Prior art keywords
compound
hydrogen
lower alkyl
formula
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US07/434,849
Inventor
David F. Crowe
Masato Tanabe
Richard Peters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SRI International Inc
Original Assignee
SRI International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SRI International Inc filed Critical SRI International Inc
Priority to US07/434,849 priority Critical patent/USRE34136E/en
Application granted granted Critical
Publication of USRE34136E publication Critical patent/USRE34136E/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0062—Estrane derivatives substituted in position 17 alfa not substituted in position 17 beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0096—Alkynyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic

Definitions

  • This invention concerns 9 ⁇ ,11 ⁇ - and 11 ⁇ -substituted estranes and their manufacture and their uses as active estrogenic and postcoital contraceptive agents.
  • estradiol has been among the most studied and is among the most active. Estradiol preparations are marketed commercially such as the product sold under the tradename Estrace. Estradiol is not orally active and must be administered parenterally.
  • Ethynyl estradiol is also widely employed together with progestins such as norethindrone and noresthindrone acetate in oral contraceptives to give products substantially superior in effectiveness to materials without ethynyl estradiol.
  • progestins such as norethindrone and noresthindrone acetate
  • examples of these ethynyl estradiol-containing contraceptive products include materials marketed under the proprietary names of Brevicon, Demulen, Loestrin, Modicon, Norinyl, Ortho-Novum, Ovcon, Oural, and Tri-Norinyl.
  • estradiol and ethynyl estradiol are substantial, as evidenced by their wide commercial adoption, these products are not without their drawbacks.
  • These problems are extremely serious when viewed in terms of the large number of women who take preparations such as those listed above on a long and regular basis.
  • These problems include enhancing the risk of endometrial carcinoma; induction of malignant carcinoma especially in the servix, breast, vagina and liver; promotion of gallbladder disease, thromboembolic and thrombotic diseases, myocardial infarction, hepatic adenoma, elevated blood pressure, and hypercalcemia; and a worsening of glucose tolerance.
  • These problems tend to manifest themselves at the dosage levels needed to achieve the desired primary estrogenic and contraceptive effects. Many of these side effects are considered to be dose-related. If more potent oral estrogens were available, they could be used in lower doses and the side effects could, at least in part, be reduced or eliminated.
  • the present invention provides a family of such more active estrogens.
  • the following publications and United States patent are believed to be of interest to these new materials and their preparation: P. J. Sykes and F. J. Rutherford, Tet. Lett. 37, 3393, (1971); K. Tsuda, S. Nozoe and Y. Okada, Chem. Parm. Bull. 11, (8), 1022, (1963); B. Magerlein and J. Hogg, J. Am. Chem. Soc. 80 2220 (1958); J. Baran, J. Med. Chem. 10, 1188, (1967); and U.S. Pat. No. 3,755,574,issued Aug. 28, 1973.
  • the present invention provides materials not shown by them and provides easier access to the general class of 11 ⁇ and 9 ⁇ ,11 ⁇ -substituted estranes not previously available.
  • the present invention in one aspect provides these derivatized analogues of estradiol and ethynyl estradiol as new chemical compounds having the chemical formula ##STR2##
  • R 1 is hydrogen, a lower alkyl or cycloalkyl or a lower acyl
  • R 2 is a nitrate, a halo, a lower alkyl or a hydroxyl
  • R 3 is hydrogen, hydroxyl or a lower alkoxy
  • R 4 is either a carbonyl oxygen or is a pair of groups, the alpha position one of which is hydrogen or a lower alkynyl and the beta one of which is hydroxyl, a lower alkyl or a N alkanoic acid ester
  • R 5 is hydrogen or a lower alkyl.
  • this invention provides new estrogenic and postcoital contraceptive pharmaceutical preparation containing effective dosing amounts of these compounds and unit dosage forms thereof.
  • the invention molecules provide the use of an additional material wherein R 1 is lower acyl, R 2 is nitrate, R 3 is hydroxyl, R 4 is a carboxyl carbon and R 5 is hydrogen. This material is shown by Sikes above but its use in such pharmaceutical products is believed new.
  • the present invention provides methods of treatment to obtain estrogenic and postcoital contraceptive effects in a mannal by administering to said mammal an effective dose of the compounds (or more commonly the pharmaceutical preparations) of the invention.
  • this invention provides a process for introducing substituents into the 11 ⁇ and the 9 ⁇ positions in an estrane, which process has the steps of first treating an R1, R4 and R5-substituted estrane with about four equivalents of ceric ammonium nitrate and R 2 - and R 3 -inserting nucleophiles. This can insert nitrate, halo or alkoxy R 2 groups and hydroxy or alkoxy R 3 groups into the structure.
  • the same insertions can be accomplished starting with the ⁇ 9,11 equivalent starting steroid and using 2 equivalents of ceric ammonium nitrate in place of 4 equivalents of ceric ammonium nitrate.
  • the R 3 group can be moved by treatment with a silane followed by BF 3 in ether.
  • An R 2 nitro group can be converted to hydroxyl by reduction using a zinc catalyst. This reduction can also be carried out prior to removal of the R 3 group in which case the final product has OH's and R 2 and as R 3 .
  • lower alkyl means a branched or unbranched saturated hydrocarbon group of one to four carbon atoms such as, methyl, ethyl, i-propyl and n-butyl and the like.
  • methyl and ethyl are preferred "lower alkyls” with methyl in general being the more preferred.
  • cycloalkyl means a cyclic saturated hydrocarbon group of four to seven carbon atoms such as cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • lower acyl means an R--CO-- group wherein R is a lower alkyl of one to three carbon atoms such that the acyl contains a total of from two to four carbon atoms.
  • R is a lower alkyl of one to three carbon atoms such that the acyl contains a total of from two to four carbon atoms.
  • CH 3 --CO-- is preferred.
  • lower alkoxy means an R--O-- group wherein R is a lower alkyl as defined above.
  • R is a lower alkyl as defined above.
  • those having one or two carbon atoms are preferred with one carbon alkoxies (methoxy) being more preferred.
  • halo and halogen mean a fluoro, chloro, bromo, or iodo substituent in an organic molecule. Of the halos, chloro and bromo are generally preferred with chloro generally being the more preferred.
  • lower alkynyl means a linear or branched hydrocarbon chain containing from two to four carbon atoms, between two of which is a carbon-carbon acetylenic triple bond.
  • Ethynyl and prop-2-ynyl are representative lower alkynyls with ethynyl being the preferred species.
  • alkanoic acid ester means a group of the formula R--COO--, wherein R is a one to seven carbon atom alkyl.
  • esters include, for example, acetate, propionate, butyrate, enanthate and the like.
  • the acetic acid ester, CH 3 --COO-- is generally preferred.
  • carbonyl oxygen means an oxygen atom attached to a carbon atom through a C ⁇ O bond.
  • R 1 may be hydrogen, lower alkyl cycloalkyl or lower acyl. Although not known with certainty, it is believed that the latter two groups undergo cleavage in use of the body so that all of these R 1 groups are essentially equivalent from an activity point of view. R 1 groups that are preferred because of their simplicity are H--, CH 3 -- and CH 3 --CO--.
  • R 2 can be nitro, halo, lower alkoxy or hydroxyl.
  • halos Cl, Br, and F are preferred with Br and Cl being more preferred.
  • lower alkoxies methoxy is preferred.
  • R 3 can be hydrogen, hydroxyl or a lower alkoxy. (As above, methoxy is the preferred alkoxy.)
  • R 4 represents two bonds. These can be present as a single carbonyl oxygen or they can go to two groups which are arrayed in an alpha and beta configuration.
  • the alpha group may be hydrogen or a lower alkynyl, especially ethynyl.
  • the beta group may be hydroxyl, a lower alkyl or an alkanoic acid ester.
  • a consideration regarding the choice of R 4 is that the alkynyl alpha substituent may enhance the oral activity of the product significantly.
  • unexpected significant oral activities in some cases 7 to 15 times that of ethynyl estradiol) are noted with materials having a carbonyl oxygen R 4 and with molecules having a beta hydroxyl R 4 .
  • R 5 is a lower alkyl or a hydrogen.
  • each of R 1 , R 2 , R 3 , R 4 , and R 5 is not made entirely independently of one another.
  • R 5 should be a lower alkyl.
  • R 3 should be hydrogen and when R 2 is hydroxyl, R 5 should be a lower alkyl to fall within the scope of this invention.
  • the compounds having a nitrate R 2 are preferred. Special preference is given to the compounds set forth in Table 1. In this table the compounds are identified by listing their R 1 through R 5 substituents.
  • R 2 and R 3 substituted compounds of this invention can be prepared using one or more of the following reactions: ##STR4##
  • R 1 , R 4 and R 5 can be as defined above.
  • a nitrate R 2 group can be inserted by the use of ceric ammonium nitrate.
  • Halo R 2 's can be inserted by the use of ceric ammonium nitrate together with a halo-containing nucleophile such as lithium chloride or lithium bromide or the like.
  • An alkoxy R 2 can be inserted by the use of ceric ammonium nitrite together with the alkanol corresponding to the alkoxy.
  • the R 3 group will be OH if no alkanol is present and can be alkoxy if alkanol is present.
  • This reaction is generally carried out using excess ceric ammonium nitrate, i.e., a 1.5 to 10 molar excess.
  • a polar solvent especially 80-100% acetic acid and stirred at low to moderate temperature such as 5° to 40° C. for from about 1 hour to about 24 hours.
  • halo R 2 's an excess (2 to 20 molar) of halo nucleophile is used. It is added together with the ceric ammonium nitrate.
  • the polar solvent such as acetic acid solvent many at least in part be replaced by the alkanol.
  • the compounds of this invention wherein R 3 is hydrogen can be formed from the above-described 9,11-substituted materials by treatment with silane followed by reduction with boron trifluoride etherate.
  • the silane employed may be a trialkyl silane such as trimethyl silane or triethyl silane. Generally a molar excess of silane and boron trifluoride etherate are employed. This reaction is generally carried out in dry solvent, such as dry methylene chloride, dry ethylene chloride or the like under an inert atmosphere initially at low temperatures such as -15° to 10° and thereafter at moderate temperatures such as 10° to 50° C.
  • R 2 --ONO 2 groups can be converted to --OH's using zinc in the reaction ##STR6##
  • This reaction is generally carried out using an excess of powdered zinc in a polar solvent such as glacial acetic acid.
  • This reaction is preferably conducted under an inert atmosphere and can be completed at temperatures of from 10° to 50° C. in from 0.1 to about 2 hours.
  • a carbonyl R 4 substituent can be converted to an alpha hydrogen and a beta hydroxyl by reduction with excess sodium borohydride.
  • This reaction can be carried out in a dry oxyhydrocarbon solvent such as anhydrous lower alkanols or the like. Suitable reaction conditions are from 5 minutes to 30 minutes at temperatures of from 10° to 50° C., preferably 20° to 50° C.
  • R 4 groups can be carried out.
  • a Grignard-type reaction can be carried out to react the R 4 carbonyl with an alkyl, alkenyl, or alkynyl magnesium bromide thereby converting the R 4 to the corresponding alpha alkyl, alkenyl or alkynyl, beta hydroxy R 4 .
  • This reaction can be carried out by gradually adding the carbonyl oxygen-containing steroid to a stirred solution of the magnesium bromide reagent is low temperature such as -10° to 20° C. for a time of from a few hours (for example 5) to several days. Water should be excluded from this reaction. THF or another aprotic solvent can be used as the reaction medium for this reaction.
  • the products or intermediates can be collected and worked up by methods known in the art, including, without limitation, extraction, chromatography such as high pressure liquid chromatography, thin layer chromatography, paper chromatography, and liquid chromatography, precipitation, crystallization and the like.
  • Example 2 The procedure of Example 1 was repeated but employing ethynyl estradiol acetate (1.0 g) as the staring material. This gave 300 mg of 3 on crystallization from ether. An analytical sample was prepared by recrystallization from ether; mp 173°-175°.
  • Example 2 The procedure of Example 1 was repeated but employing 1 g of 3-hydroxy-19 norpregna-1,3,5(10)-trien 3-acetate. This gave, on crystallization from ether-petroleum-ether, 350 mg of 4. An analytical sample was prepared by recrystallization from ether; mp 177°-179°.
  • Example 2 The procedure of Example 1 was repeated but employing 7 ⁇ -methyl-19-norpregna-1,3,5(10)-trien. This gave, on separation by preparative tlc, 59 mg of 5. An analytical sample was prepared by recrystallization from ether; mp 140°-143°.
  • Example 6 The process of Example 6 is repeated substituting as feed stock, 150 mg of the nitrate ester produced in Example 9. This gave, on crystallization from ether, 100 mg of 15: mp 180°-182°.
  • 1-chloro-1,2,2-trifluoroethylene was bubbled into 50.0 g of triethylamine for 8 hr at -5° to -10°.
  • the reaction was the distilled under reduced pressure to yield 61 g of product, bp 35°/6 mm (lit 10 bp 32°-33°/6 mm).
  • the 2-chloro-1,1,2-trifluorotriethylamine was stored in vials under nitrogen, wrapped in aluminum foil and placed in a desicator.
  • the ether phase was separated and washed with water.
  • the ether solution was dried over sodium sulfate and evaporated at reduced pressure to yield 2.70 g of crude 21.
  • the crude product was purified by hplc to yield 0.750 g of 21, which was recrystallized from methanol to yield 0.550 g; mp 129.5-130.0.
  • dry acetylene was prepared by passing the gas through two traps (one cooled with dry-ice/acetone); and then through a column of KOH pellets, Drierite, and KOH pellets.
  • the dry acetylene was bubbled into 25.0 ml of dry THNR at 0°-5° for 1.5 hr.
  • To the acetylene solution was added dropwise 0.766 ml of 3.0 ethyl magnesium bromide. The reaction was stirred for an additional 0.20 hr at 0°-5°.
  • Compound 18 was prepared using the general techniques taught herein.
  • Example 1 The process of Example 1 is repeated but using 5 g of strone acetate as starting material. This gave, on crystallization from ether, 2.1 g of 20. An analytical sample was prepared by recrystallization from ether. The sample (m.p. 183°-184°) had spectral properties consistent with the structure of 20.
  • the compounds of this invention exhibit significant estrogenic activity and postcoital contraceptive activity. This is demonstrated in the following tests.
  • the estrogenic activity was determined using immature female rates ovariectomized at 21 days of age. Treatment was by oral administration for 4 days, beginning on the day of ovariectomy. Animals were autopsied on the day following the last administration of test compound. Vaginal smears were obtained from animals that had open vaginas at the time of autopsy. The endpoints for comparison with a standard estrogen will be the increase in uterin weight and cornification of vaginal smears. (The test compounds were diluted with a 0.5% Carboxymethyl cellulose suspension.)
  • Oral postcoital activity was determined using adult cycling female rats, obtained from the Holtzman Rat Company, were selected in the proestrous phase of the cyle. Treatment began on the day of proestrus. Each female was caged overnight with two adult males. The find of sperm in the vaginal smear the following morning was used as evidence of insemination. Treatment was continued for a total of 8 days. The rats were sacrificed on the day following the last treatment, and the number of implantation sites and the number of corpora lutea were counted. The test material was administered parenterally (sc or im or orally by intubation).
  • Immature 18-day-old rats are assigned randomly to groups of 5 to 10. Treatment by S.C. injection is started on the day the animals arrive and continues once daily for 4 days. On day 5, vaginal smears are obtained, and uteri--carefully dissected between precise areas between the cervix and the oviduct--are stripped of fat and connective tissue and then weighed on a torsion balance. Fluid in uteri is expressed before weighing. Body weights of rats are recorded on the first day and at autopsy.
  • the compounds of this invention can be administered to humans or other mammals by any of the accepted modes of administration for steroidal agents. These methods include oral, parenteral, suppositories, topical and the like.
  • the compounds can be administered alone or as part of a combination product--such as with a progestin or the like.
  • compositions used may be in the form of solid, semisolid or liquid dosage forms, such as, for example, injectables, tablets, suppositories, pills, capsules, powders, liquids, suspensions, or the like, preferably in unit dosage forms suitable for single administration of precise dosages.
  • the compositions will include a conventional pharmaceutical carrier or excipient and an active compound of the invention and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, etc.
  • a pharmaceutically acceptable non-toxic composition is formed by the incorporation of any of the normally employed excipients, such as, for example pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, sucrose, magnesium, carbonate, and the like.
  • excipients such as, for example pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, sucrose, magnesium, carbonate, and the like.
  • Such compositions take the form of solutions, suspensions, tablets, pills, capsules, powders, sustained release formulations and the like.
  • the compounds of the invention as defined above may be formulated as suppositories using, for example, polyalkylene glycols, for example, propylene glycol, as the carrier.
  • Liquid pharmaceutically administerable compositions particularly for parenteral administration can be prepared by dissolving, dispersing, etc. a compound of the invention and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension.
  • a carrier such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like
  • the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, etc.
  • composition of formulation to be administered will, in any event, contain a quantity of the active compounds(s) adequate to achieve the desired estrogenic or contraceptive effect in the subject being treated.
  • the amount of active compound administered will, of course, be dependent on the activity of the compound, the effect desired and the view of the attending physician.
  • conventional oral estradiol pills and tablets may contain from 0.5 to about 2 mg of active material, while a dose of injectable estradiol may be from about 1 to about 10 mg of the active material.
  • Oral ethynyl estradiol tablets usually contain in the range of from 0.01 to 1 mg of the active material.
  • Oral contraceptives employing ethynyl estradiol generally contain from about 0.02 to about 0.1 mg of ethynyl estradiol. In view of the activities demonstrated with compounds of this invention one could obtain desired responses with from as little as 0.0002 mg of active material to as much as 5 or 10 mg.
  • the following nonlimiting representative product formulations further illustrate the use of the present materials in pharmaceutical composition.
  • Hard shell gelatin capsules are filled with 200 mg of the above mixture to achieve a unit dosage form for 0.05 mg estrogen therapy.
  • a vaginal cream is formulated by admixing 0.15 mg/g of final product of Example 12 in a cream base made up of glycerin, mineral oil, glycerol monostearate, polyethylene glycol ether complex of fatty acids, cetyl alcohol, lanolin. When one cc of this product is administered an estrogenic response is achieved.
  • the above materials are intimately mixed and formed into 1000 250 mg tablets each of which delivers 1.25 mg of androgen and 0.10 mg of estrogen.
  • the above ingredients are mixed and formed into 250 mg tablets which when administered to a female exhibit contraceptive activity.
  • the above ingredients are mixed and formed into 250 mg tablets which when administered to a female human exhibit postcoital contraceptive activity.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Steroid Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Liquid Crystal Substances (AREA)
  • Saccharide Compounds (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Silicon Compounds (AREA)

Abstract

9 alpha, 11 beta and 11 beta-substituted estranes are disclosed which exhibit elevated estrogenic and postcoital contraceptive activities. A process for their manufacture and their use in pharmaceuticals is also disclosed.

Description

ORIGIN OF THE INVENTION
This invention was made in performance of a United States government contract, No. NO1-HD-5-2844 issued by the National Institutes of Health.
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention concerns 9α,11β- and 11β-substituted estranes and their manufacture and their uses as active estrogenic and postcoital contraceptive agents.
2. General Background and Prior Art
It has long been recognized that estrogenic hormones are important pharmacologial materials which find a wide range of beneficial applications in human and veterinary therapy. Such applications include, for example, supplementing the estrogen levels in persons in need of the same; incorporation into birth control devices and compositions; and the like. Of the available natural and synthetic estrogens, estradiol has been among the most studied and is among the most active. Estradiol preparations are marketed commercially such as the product sold under the tradename Estrace. Estradiol is not orally active and must be administered parenterally.
It has also been long recognized that estrogens which are orally active are very attractive because of the obvious advantages of nontraumatic oral administration. In the late 1930's, Inhoffen et al described ethynyl estradiol (19-Nor-17A-pregna-1,3,5(10)triene-20-yne-3,17-diol. ##STR1## Naturwiss, 26, 96 (1938). This material is noted in such other early references as Inhoffen, et al. Ber. 71, 1024 (1938); German Pat. No. 702,063; British Pat. No. 516,444; and U.S. Pat. Nos. 2,243,887; 2,251,939; 2,265,976; and 2,267,257. As early as 1951, (Petit et al. Bull. Soc. Chim. France, 1951, 121) it was recognized that the material produced estrogenic effects in mammals when administered orally. This had led to its wide adoption as an oral estrogen and its marketing in a range of products and dosage forms under such proprietary names as, for example, Diogyn-E, Dyloform, Etinestryl, Ethidol, Estinyl, Etivex, Feminone, Inestra, Kolpolyn, Linoral, Lynoral, Novestrol, Oradiol, Orestralyn, Primogyn, and Progynon.
Ethynyl estradiol is also widely employed together with progestins such as norethindrone and noresthindrone acetate in oral contraceptives to give products substantially superior in effectiveness to materials without ethynyl estradiol. Examples of these ethynyl estradiol-containing contraceptive products include materials marketed under the proprietary names of Brevicon, Demulen, Loestrin, Modicon, Norinyl, Ortho-Novum, Ovcon, Oural, and Tri-Norinyl.
While the advantages of estradiol and ethynyl estradiol are substantial, as evidenced by their wide commercial adoption, these products are not without their drawbacks. These problems are extremely serious when viewed in terms of the large number of women who take preparations such as those listed above on a long and regular basis. These problems include enhancing the risk of endometrial carcinoma; induction of malignant carcinoma especially in the servix, breast, vagina and liver; promotion of gallbladder disease, thromboembolic and thrombotic diseases, myocardial infarction, hepatic adenoma, elevated blood pressure, and hypercalcemia; and a worsening of glucose tolerance. These problems tend to manifest themselves at the dosage levels needed to achieve the desired primary estrogenic and contraceptive effects. Many of these side effects are considered to be dose-related. If more potent oral estrogens were available, they could be used in lower doses and the side effects could, at least in part, be reduced or eliminated.
The present invention provides a family of such more active estrogens. The following publications and United States patent are believed to be of interest to these new materials and their preparation: P. J. Sykes and F. J. Rutherford, Tet. Lett. 37, 3393, (1971); K. Tsuda, S. Nozoe and Y. Okada, Chem. Parm. Bull. 11, (8), 1022, (1963); B. Magerlein and J. Hogg, J. Am. Chem. Soc. 80 2220 (1958); J. Baran, J. Med. Chem. 10, 1188, (1967); and U.S. Pat. No. 3,755,574,issued Aug. 28, 1973. In comparison to the disclosures of these references, the present invention provides materials not shown by them and provides easier access to the general class of 11β and 9α,11β-substituted estranes not previously available.
It is important to recognize that, notwithstanding the large volume of effort that has been devoted to research into the preparation and production and the testing of synthetic and naturally occurring steroids such as the estrogens, this is still very much an empirical field. Simple or seemingly insignificant shifts in one or two atoms or groups in a steroid can render a new compound active or inactive or change dramatically the entire character of its activity.
STATEMENT OF THE INVENTION
We have now discovered that certain 11β and 9α,11β-substituted derivatives of estradiol, and in some instances in particular of ethynyl estradiol, offer estrogenic activity and postcoital contraceptive activity which is in many cases many times greater than that obtained with nonderivatized material. Thus, the present invention in one aspect provides these derivatized analogues of estradiol and ethynyl estradiol as new chemical compounds having the chemical formula ##STR2## In this formula, R1 is hydrogen, a lower alkyl or cycloalkyl or a lower acyl; R2 is a nitrate, a halo, a lower alkyl or a hydroxyl; R3 is hydrogen, hydroxyl or a lower alkoxy; R4 is either a carbonyl oxygen or is a pair of groups, the alpha position one of which is hydrogen or a lower alkynyl and the beta one of which is hydroxyl, a lower alkyl or a N alkanoic acid ester; and R5 is hydrogen or a lower alkyl. When R2 is nitrate, R3 is hydroxyl, and R4 is carbonyl, R5 must be a lower alkyl. When R2 is a halo R3 must be hydrogen. When R2 is hydroxyl R5 must be a lower alkyl. In other aspects this invention provides new estrogenic and postcoital contraceptive pharmaceutical preparation containing effective dosing amounts of these compounds and unit dosage forms thereof. In this aspect, the invention molecules provide the use of an additional material wherein R1 is lower acyl, R2 is nitrate, R3 is hydroxyl, R4 is a carboxyl carbon and R5 is hydrogen. This material is shown by Sikes above but its use in such pharmaceutical products is believed new. In yet another aspect the present invention provides methods of treatment to obtain estrogenic and postcoital contraceptive effects in a mannal by administering to said mammal an effective dose of the compounds (or more commonly the pharmaceutical preparations) of the invention. In a yet further aspect, this invention provides a process for introducing substituents into the 11β and the 9α positions in an estrane, which process has the steps of first treating an R1, R4 and R5-substituted estrane with about four equivalents of ceric ammonium nitrate and R2 - and R3 -inserting nucleophiles. This can insert nitrate, halo or alkoxy R2 groups and hydroxy or alkoxy R3 groups into the structure.
The same insertions can be accomplished starting with the Δ9,11 equivalent starting steroid and using 2 equivalents of ceric ammonium nitrate in place of 4 equivalents of ceric ammonium nitrate. The R3 group can be moved by treatment with a silane followed by BF3 in ether. An R2 nitro group can be converted to hydroxyl by reduction using a zinc catalyst. This reduction can also be carried out prior to removal of the R3 group in which case the final product has OH's and R2 and as R3.
DETAILED DESCRIPTION OF THE INVENTION
In this specification and in the claims which follow it reference will be made to a number of terms which shall be defined to have the following meanings:
"lower alkyl" means a branched or unbranched saturated hydrocarbon group of one to four carbon atoms such as, methyl, ethyl, i-propyl and n-butyl and the like. For use herein, methyl and ethyl are preferred "lower alkyls" with methyl in general being the more preferred.
"cycloalkyl" means a cyclic saturated hydrocarbon group of four to seven carbon atoms such as cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
"lower acyl" means an R--CO-- group wherein R is a lower alkyl of one to three carbon atoms such that the acyl contains a total of from two to four carbon atoms. Of the lower acyls, CH3 --CO-- group wherein R is a lower alkyl of one to three carbon atoms such that the acyl contains a total of from two to four carbon atoms. Of the lower acyls, CH3 --CO-- (acetyl) is preferred.
"lower alkoxy" means an R--O-- group wherein R is a lower alkyl as defined above. Of the lower alkoxies, those having one or two carbon atoms are preferred with one carbon alkoxies (methoxy) being more preferred.
"halo" and "halogen" mean a fluoro, chloro, bromo, or iodo substituent in an organic molecule. Of the halos, chloro and bromo are generally preferred with chloro generally being the more preferred.
"lower alkynyl" means a linear or branched hydrocarbon chain containing from two to four carbon atoms, between two of which is a carbon-carbon acetylenic triple bond. Ethynyl and prop-2-ynyl are representative lower alkynyls with ethynyl being the preferred species.
"alkanoic acid ester" means a group of the formula R--COO--, wherein R is a one to seven carbon atom alkyl. Such esters include, for example, acetate, propionate, butyrate, enanthate and the like. The acetic acid ester, CH3 --COO-- is generally preferred.
"carbonyl oxygen" means an oxygen atom attached to a carbon atom through a C═O bond.
In describing the location of groups and substituents on the estradiol and ethynyl estradiol rings, the following numbering system will be employed. ##STR3## In these structures, the use of solid and dashed lines to denote particular conformation of groups follows the IUPAC steroid-naming convention.
In the compounds of the invention which are set forth in the structural formula given in the Statement of the Invention, R1 may be hydrogen, lower alkyl cycloalkyl or lower acyl. Although not known with certainty, it is believed that the latter two groups undergo cleavage in use of the body so that all of these R1 groups are essentially equivalent from an activity point of view. R1 groups that are preferred because of their simplicity are H--, CH3 -- and CH3 --CO--.
R2 can be nitro, halo, lower alkoxy or hydroxyl. Among the halos, Cl, Br, and F are preferred with Br and Cl being more preferred. Among the lower alkoxies methoxy is preferred.
R3 can be hydrogen, hydroxyl or a lower alkoxy. (As above, methoxy is the preferred alkoxy.)
R4 represents two bonds. These can be present as a single carbonyl oxygen or they can go to two groups which are arrayed in an alpha and beta configuration. The alpha group may be hydrogen or a lower alkynyl, especially ethynyl. The beta group may be hydroxyl, a lower alkyl or an alkanoic acid ester. A consideration regarding the choice of R4 is that the alkynyl alpha substituent may enhance the oral activity of the product significantly. Importantly, however, with some of the compounds of this invention unexpected significant oral activities (in some cases 7 to 15 times that of ethynyl estradiol) are noted with materials having a carbonyl oxygen R4 and with molecules having a beta hydroxyl R4.
R5 is a lower alkyl or a hydrogen.
The selection of each of R1, R2, R3, R4, and R5 is not made entirely independently of one another. For example, when R2 is nitro, and R3 is OH and R4 is a carbonyl oxygen, R5 should be a lower alkyl. Similarly, when R2 is a halo, R3 should be hydrogen and when R2 is hydroxyl, R5 should be a lower alkyl to fall within the scope of this invention.
As a general class, the compounds having a nitrate R2 are preferred. Special preference is given to the compounds set forth in Table 1. In this table the compounds are identified by listing their R1 through R5 substituents.
              TABLE 1                                                     
______________________________________                                    
Compound                                                                  
Identification                                                            
No.*      R.sub.1 R.sub.2  R.sub.3                                        
                                  R.sub.4                                 
                                         R.sub.5                          
______________________________________                                    
1         Ac**    --ONO.sub.2                                             
                           OH     ═O CH.sub.3                         
3         Ac      --ONO.sub.2                                             
                           OH     α C.tbd.C                         
                                         H                                
                                  β OAc                              
4         Ac      --ONO.sub.2                                             
                           OH     α H                               
                                         H                                
                                  β ethyl                            
5         Ac      --ONO.sub.2                                             
                           OH     α H                               
                                         CH.sub.3                         
                                  β ethyl                            
6         Ac      --ONO.sub.2                                             
                           H      ═O CH.sub.3                         
8         H       --ONO.sub.2                                             
                           H      α H                               
                                         CH.sub.3                         
                                  β OH                               
7         Ac      --ONO.sub.2                                             
                           H      ═O H                                
10        Ac      --ONO.sub.2                                             
                           OCH.sub.3                                      
                                  ═O H                                
27        CH.sub.3                                                        
                  Cl       H      α C.tbd.C                         
                                         H                                
                                  β OH                               
18        CH.sub.3                                                        
                  Cl       H      α H                               
                                         H                                
                                  β ethyl                            
11        Ac      Cl       H      ═O H                                
12        H       OH       OH     α C.tbd.C                         
                                         CH.sub.3                         
13        Ac      OH       OH     ═O CH.sub.3                         
14        Ac      OH       H      ═O CH.sub.3                         
9         Ac      OCH.sub.3                                               
                           OCH.sub.3                                      
                                  ═O H                                
15        Ac      OCH.sub.3                                               
                           H      ═O H                                
16        CH.sub.3                                                        
                  OCH.sub.3                                               
                           OH     ═O H                                
19        H       OCH.sub.3                                               
                           H      α H                               
                                         H                                
                                  β ethyl                            
______________________________________                                    
 *This is also the number of the example in which the compound is         
 demonstrated.                                                            
 **CH.sub.3 --CO
The R2 and R3 substituted compounds of this invention can be prepared using one or more of the following reactions: ##STR4##
In this reaction, R1, R4 and R5 can be as defined above. A nitrate R2 group can be inserted by the use of ceric ammonium nitrate. Halo R2 's can be inserted by the use of ceric ammonium nitrate together with a halo-containing nucleophile such as lithium chloride or lithium bromide or the like. An alkoxy R2 can be inserted by the use of ceric ammonium nitrite together with the alkanol corresponding to the alkoxy. The R3 group will be OH if no alkanol is present and can be alkoxy if alkanol is present.
This reaction is generally carried out using excess ceric ammonium nitrate, i.e., a 1.5 to 10 molar excess. When forming compounds having a nitrate R2 group the starting steroid and the ceric ammonium nitrate are mixed, generally in a polar solvent, especially 80-100% acetic acid and stirred at low to moderate temperature such as 5° to 40° C. for from about 1 hour to about 24 hours. When adding halo R2 's an excess (2 to 20 molar) of halo nucleophile is used. It is added together with the ceric ammonium nitrate. When adding alkoxy R2 's, the polar solvent such as acetic acid solvent many at least in part be replaced by the alkanol.
In all cases excess water is to be avoided and an inert gas cap over the reaction vessel is preferred.
Alternatively, one can use the 9,11Δ steroids as starting material in the reaction ##STR5## In this reaction, less ceric ammonium nitrate (2 moles rather than 4) is consumed. The same reaction conditions as above can be used.
The compounds of this invention wherein R3 is hydrogen (i.e., the 11-substituted materials) can be formed from the above-described 9,11-substituted materials by treatment with silane followed by reduction with boron trifluoride etherate. The silane employed may be a trialkyl silane such as trimethyl silane or triethyl silane. Generally a molar excess of silane and boron trifluoride etherate are employed. This reaction is generally carried out in dry solvent, such as dry methylene chloride, dry ethylene chloride or the like under an inert atmosphere initially at low temperatures such as -15° to 10° and thereafter at moderate temperatures such as 10° to 50° C.
R2 --ONO2 groups can be converted to --OH's using zinc in the reaction ##STR6## This reaction is generally carried out using an excess of powdered zinc in a polar solvent such as glacial acetic acid. This reaction is preferably conducted under an inert atmosphere and can be completed at temperatures of from 10° to 50° C. in from 0.1 to about 2 hours.
A carbonyl R4 substituent can be converted to an alpha hydrogen and a beta hydroxyl by reduction with excess sodium borohydride. This reaction can be carried out in a dry oxyhydrocarbon solvent such as anhydrous lower alkanols or the like. Suitable reaction conditions are from 5 minutes to 30 minutes at temperatures of from 10° to 50° C., preferably 20° to 50° C.
Other changes to R4 groups can be carried out. For example, a Grignard-type reaction can be carried out to react the R4 carbonyl with an alkyl, alkenyl, or alkynyl magnesium bromide thereby converting the R4 to the corresponding alpha alkyl, alkenyl or alkynyl, beta hydroxy R4. This reaction can be carried out by gradually adding the carbonyl oxygen-containing steroid to a stirred solution of the magnesium bromide reagent is low temperature such as -10° to 20° C. for a time of from a few hours (for example 5) to several days. Water should be excluded from this reaction. THF or another aprotic solvent can be used as the reaction medium for this reaction.
After any of these reactions the products or intermediates can be collected and worked up by methods known in the art, including, without limitation, extraction, chromatography such as high pressure liquid chromatography, thin layer chromatography, paper chromatography, and liquid chromatography, precipitation, crystallization and the like.
The invention will be further described by the following examples. These are provided only to illustrate embodiments of the invention and are not to be construed as limitations on the invention's scope.
EXAMPLE 1 3,9α,11β-Trihydroxy-7α-methyl-estra-1,3,5(10)-trien-17-one 3-acetate 11-nitrate ester (1)
To a stirred solution of 20 g (64.3 mM) of 7α-methylestrone acetate in 400 ml of 90% acetic acid under a nitrogen atmosphere, 140 g (266 mM) of ceric ammonium nitrate was added. The reaction mixture was stirred for 6 hr at room temperature and then added to 2 l of water. The precipitated products were extracted into 750 ml of ether, and the aqueous phase was extracted with an additional 750 ml of ether. The ether extracts were combined and washed--three times with 750 ml portions of water, once with 750 ml of a 5% sodium bicarbonate solution, and once with 750 ml of water. The ether solution was dried over sodium sulfate, and then the ether was removed at reduced pressure to afford 24.8 g of residue. Crystallization from ether gave 10.5 g of 1. An analytical sample was prepared by recrystallization from ether; mp, 184°-186°.
Anal. high-resolution mass spec. for C21 H25 O5 (M--NO2): Calcd. 357.1702; Found: 357.1712
EXAMPLE 2
Treatment of Δ9,11-7α-methylestrone acetate with two equivalents of ceric ammonium nitrate gave 1 identical to the material obtained above.
EXAMPLE 3 17α-Ethynyl-3,9α,11β-17β-tetrahydroxy-estra-1,3,5(10)-trien 3,17-Diacetate 11-Nitrate Ester (3)
The procedure of Example 1 was repeated but employing ethynyl estradiol acetate (1.0 g) as the staring material. This gave 300 mg of 3 on crystallization from ether. An analytical sample was prepared by recrystallization from ether; mp 173°-175°.
Anal. high resolution mass spec. for C24 H27 NO8 : Calcd. 357.2066. Found: 357.2103
EXAMPLE 4 3,9α,11β-Trihydroxy-19-norpregna-1,3,5(10)-trien 3-Acetate 11-Nitrate Ester (4)
The procedure of Example 1 was repeated but employing 1 g of 3-hydroxy-19 norpregna-1,3,5(10)-trien 3-acetate. This gave, on crystallization from ether-petroleum-ether, 350 mg of 4. An analytical sample was prepared by recrystallization from ether; mp 177°-179°.
EXAMPLE 5 3,9α,11β-Trihydroxy-7α-methyl-19-norpregna-1,3,5(10)-trien 3-Acetate 11-Nitrate Ester (5)
The procedure of Example 1 was repeated but employing 7α-methyl-19-norpregna-1,3,5(10)-trien. This gave, on separation by preparative tlc, 59 mg of 5. An analytical sample was prepared by recrystallization from ether; mp 140°-143°.
Anal. high resolution mass spec. for C23 H31 O4 (MNO2): Calcd. for 371.222; Found: 371.2231.
EXAMPLE 6 3.11β-Dihydroxy-7α-methyl-estra-1,3,5(10)-trien-17-one 3-acetate 11-nitrate ester (6)
To a stirred solution of 10.5 g (25.5 mM) of 1 in 400 ml of dry methylene chloride under a nitrogen atmosphere at salt-ice bath temperature, 10 g (76.5 mM) of triethyl silane followed by 26.8 ml of boron trifluoride etherate were added. The reaction mixture was stirred for 1 hr and then warmed to room temperature. The methylene chloride solution was washed three times with 150-ml portions of a 10% potassium carbonate solution and once with 150 ml of water; then it was dried over sodium sulfate. The methylene chloride was removed at reduced pressure, and crystallization from ether gave 5.75 g of 6. An analytical sample was prepared by recrystallization from ether; mp, 195°-196°.
Anal. Cacd. for C21 H25 NO6 C, 65.10; H, 6.50; N, 3.62. Found: C, 65.11; H, 6.58; N, 3.57.
EXAMPLE 7 3,11β-Dihydroxy-estra-1,3,5(10)-trien-17-one 3-Acetate 11-Nitrate Ester (7)
Treatment of 5 g of estrone acetate with ceric ammonium nitrate by the procedure described in Example 1 gave, on crystallization from ether, 2.1 g of the intermediate ester 3,9α,11β-Trihydroxy-estra-1,3,5(10)trien-17-one 3-Acetate 11-Nitrate Ester.
By the procedures used in Example 3, 310 mg of the ester just prepared gave, on crystallization from ether, 150 mg of pure 8, mp 190°-192°.
Anal. Calcd. for C20 H23 NO6 : C, 64.33; H, 6.21; N, 3.75. Found: C, 64.09; H, 5.95; N, 3.62.
EXAMPLE 8 3,11β,17β-Trihydroxy-7α-methyl-estra-1,3,5(10)trien 11 Nitrate ester (8)
To a stirred solution of 100 mg of 6 from Example 6 in 12 ml of methanol 48 mg of sodium borohydride was added. The reaction mixture was stirred for 15 min then added to 75 ml of water. The product was extracted into 75 ml of ether and the etheral solution was washed with water then dried over sodium sulfate. The ether was removed at reduced pressure to give 100 mg of residue. An analytical sample was prepared by crystallization from methylene chloride: mp 179°-182°.
Anal. GC mass spec for C19 H25 NO5 : Calcd. for 347; Found 347.
EXAMPLES 9 AND 10 3,9α,11β-Trihydroxy-estra-1,3,5(10)-trien-17-one 3-Acetate 9α-Methy ether 11-Nitrate ester (9) and 3,9α,11β-trihydroxy-estra 1,3,5(10trien-17-one 3-Acetate 9,11-Dimethyl ether (10)
To a stirred solution of 310 mg of Δ9,11-estrone acetate in 10 ml of methanol under a nitrogen atmosphere 1.1 g of ceric ammonium nitrate was added. The reaction mixture was stirred for 45 min at room temperature then added to 100 ml of water. The reaction products were extracted into 100 ml of ether, then the etheral solution was washed twice with water then dried over sodium sulfate. The solvent was removed at reduced pressure to give 370 mg of residue. Separation by preparative thin layer chromatography gave 160 mg of 9 and 160 mg of 10.
Anal. 9 GC mass spec. for C22 H28 O5 : Calcd. for 362; Found: 362.
Anal. 10 GC mass spec. for C21 H25 NO6 : Calcd. 403; Found: 403.
EXAMPLE 11 11β-Chloro-3-hydroxy-estra-1,3,5(10)-trien-17-one 3-Acetate (11)
To a stirred solution of 1.0 g (3.3 mM) of Δ9,11-estrone acetate and 1.25 g (30 mM) of lithium chloride in 30 ml of 90% acetic acid under nitrogen was added 3.8 g (6.8 mM) of ceric ammonium nitrate. The reaction mixture was stirred for 3 hr and then added to 250 ml of ice water. The product was extracted into 100 ml of ether. The ether solution was washed three times with water, twice with 5% NaHCO3, and once with water and then dried over sodium sulfate. The solvent was removed at reduced pressure to afford 1.2 g of residue. Crystallization from ether gave 530 mg of the intermediate 11β-Chloro-3,9α-dihydroxy-estra-1,3,5(10)-trien-17-one 3-Acetate. An analytical sample was prepared by recrystallization from ether.
Anal. GC mass spec. for C20 H23 ClO4 : Calcd. for 362; Found: 362.
By the procedure used in Example 6, reaction of 362 mg of the intermediate gave, on crystallization from ether 190 mg of 11: mp 187°-190°.
Anal. GC mass spec. for C20 H23 ClO3 : Calcd. for 346; Found: 346.
EXAMPLE 12 17α-Ethylnyl-7α-methyl-estra-1,3,5(10)-trien-3,9α,11.beta.-tetraol (12)
To a stirred solution of 10 mM of ethynyl magnesium bromide in 25 ml of THF at 0° under nitrogen was added 360 mg of 3,9α,11β-trihydroxy-7-α-methyl-estra-1,3,5(10)-trien-17-one 3-acetate in 8 ml of THF dropwise over 10 min. The reaction mixture was warmed to room temperature and then stirred for 18 hr. A solution of 1 ml of saturated NH4 Cl was added and stirring was continued for 15 min. Then 100 ml of ether was added. The ether solution was washed three times with water and then dried over sodium sulfate. Removal of the solvent at reduced pressure gave 400 mg of residue. Fractionation by preparative tlc (benzene-50% ether SiGF) gave 100 mg of 12.
Anal. high resolution mass spec. for C21 H24 O3 : Calcd. for 324.1725. Found: 324.1754.
EXAMPLE 13 3,9α,11β-Trihydroxy-7α-methyl-estra-1,3,5(10)-trien-17-one 3-Acetate (13)
To a stirred solution of 2.3 g of the nitrate ester of Example 1 in 100 ml of glacial acetic acid under nitrogen was added 9.2 g of powdered zinc. The reaction mixture was stirred for 1 hr. Then the zinc suspension was added to 800 ml of ice water and the acetic acid was neutralized with 2N sodium hydroxide. The product was extracted into 400 ml of ether, and the ether solution was washed three times with water and then dried over sodium sulfate. The solvent was removed at reduced pressure to afford 1.4 g of residue. Crystallization from ether gave 361 mg of 13. An analytical sample was prepared by recrystallization from ether; mp 188°-190°.
Anal. high resolution mass spec. for C21 H26 O5 : Calcd. for 358.1780. Found: 358,1776.
EXAMPLE 14 3,11β-Dihydroxy-7α-methyl-estra-1,3,5(10)-trien-17-one 3-acetate (14)
To a stirred solution of 5.2 g of the nitrate ester of Example 6 in 150 ml of glacial acetic acid under a nitrogen atmosphere, 7.5 g of zinc dust was added. The reaction mixture was stirred for 1 hr at room temperature and then filtered through celite, and the filter cake was washed with 100 ml of glacial acetic acid. Most of the acetic acid was removed at reduced pressure; then 300 ml of water was added, and precipitated product was extracted into 500 ml of ether. The ether solution was washed twice with 150 ml of water, once with 150 ml of a 5% sodium bicarbonate solution, and with 150 ml of water; then it was dried over sodium sulfate. The ether was removed at reduced pressure to afford 4.5 g of crude 14. Crystallization from ether gave 2.3 g of pure 14. Preparative tlc (SiGF-benzene-25% ether) gave an additional 1.4 g of pure 14. An analytical sample was prepared by recrystallization from methylene chloride-ether; mp, 130°-132°.
Anal. Calcd. for C21 H26 O4 : C, 73.66; H, 7.65. Found: C, 73.84; H, 7.66.
EXAMPLE 15 3,11β-Dihydroxy-estra-1,3,5(10)-trien-17-one 3-Acetate 11-Methy ether (15)
The process of Example 6 is repeated substituting as feed stock, 150 mg of the nitrate ester produced in Example 9. This gave, on crystallization from ether, 100 mg of 15: mp 180°-182°.
Anal. GC mass spec. for C22 H26 O4 : Calcd. for 342; Found: 342.
EXAMPLE ≠ 3,9α,11β-Trihydroxy-estra-1,3,5(10)-trien-17-one 3,11-Dimethyl ether (16)
To a slurry of 284 mg of estrone methyl ether in 20 ml of methanol under a nitrogen atmosphere a solution of 3.3 g of ceric ammonium nitrate in 30 ml of methanol was added dropwise over 3 hr. The reaction mixture was added to 150 ml of water and the products were extracted into 100 ml of ether. The ether solution was washed with water then dried over sodium sulfate. The ether was removed at reduced pressure to give 300 mg of residue. Separation by preparative thin layer chromatography gave 130 mg of 16. An analytical sample was prepared by crystallization from ether: mp 191°-194°.
Anal. GC mass spec. for C20 H26 O4 : Calcd. for 330; Found: 330.
EXAMPLE 17 11β-Chloroethynylestradiol 3-Methyl Ether (17) Precursor Preparation 2-Chloro-1,1,2-trifluorotriethylamine
1-chloro-1,2,2-trifluoroethylene was bubbled into 50.0 g of triethylamine for 8 hr at -5° to -10°. The reaction was the distilled under reduced pressure to yield 61 g of product, bp 35°/6 mm (lit10 bp 32°-33°/6 mm). The 2-chloro-1,1,2-trifluorotriethylamine was stored in vials under nitrogen, wrapped in aluminum foil and placed in a desicator.
11β-Chloroestrone 3-Methyl Ether
To a solution of 3.0 g of 11α-hydyroxyestrone 3-methyl ether in 120 ml of dry THF at 0°-5° (ice-water bath) was added 0.7 g of dry lithium chloride (dried in a desiccator at 80° under vacuum at 1.0 mm for 18 hr) and 2.25 ml of the above-prepared haloamine. The reaction was stirred at this temperature for 18 hr. Tlc indicated that the reaction has not gone to completion; therefore, an additional 0.2 ml of the haloamine reagent and 0.07 g of lithium chloride were added. After being stirred for an additional hr at 0°-5°, the reaction was poured into ether and water. The ether phase was separated and washed with water. The ether solution was dried over sodium sulfate and evaporated at reduced pressure to yield 2.70 g of crude 21. The crude product was purified by hplc to yield 0.750 g of 21, which was recrystallized from methanol to yield 0.550 g; mp 129.5-130.0.
Anal. high resolution mass spec calcd for C19 H23 O2 Cl: calcd 318.1389; found 318.1410.
GRIGNARD REAGENT
dry acetylene was prepared by passing the gas through two traps (one cooled with dry-ice/acetone); and then through a column of KOH pellets, Drierite, and KOH pellets. The dry acetylene was bubbled into 25.0 ml of dry THNR at 0°-5° for 1.5 hr. To the acetylene solution was added dropwise 0.766 ml of 3.0 ethyl magnesium bromide. The reaction was stirred for an additional 0.20 hr at 0°-5°.
THE DESIRED PRODUCT (17l )
To the Grignard reagent reaction solution was then added 0.18 g of the 11β-chloroestrone-3-methyl ether in 8.0 ml of dry THF. The reaction was allowed to warm to room temperature and stirring was continued for 18 hr. To quench the reaction, 5 ml of saturated NH4 Cl was slowly added. The THF was evaporated at reduced pressure and the residue was dissolved in ether. The ether solution was washed with saturated NH4 Cl, dried over Na2 SO4 and evaporated at reduced pressure to yield 0.172 g of crude product. The crude product was chromatographed on 20 g of silica gel and eluted with benzene-7% ether to afford 0.063 g of pure 17; mp 173°-174°.
Anal. high resolution mass spec calcd for C21 H25 O2 Cl: calcd 344.15433; found 344.1555.
EXAMPLE 18
Compound 18 was prepared using the general techniques taught herein.
EXAMPLE 19
Compound 19 was prepared using the general techniques taught herein.
EXAMPLE 20
3,9 alpha,11 beta-Trihydoxy-estra-1,3,5(10)trien-17-one 3-Acetate 11-Nitrate Ester (20)
The process of Example 1 is repeated but using 5 g of strone acetate as starting material. This gave, on crystallization from ether, 2.1 g of 20. An analytical sample was prepared by recrystallization from ether. The sample (m.p. 183°-184°) had spectral properties consistent with the structure of 20.
BIOLOGICAL ACTIVITY
The compounds of this invention exhibit significant estrogenic activity and postcoital contraceptive activity. This is demonstrated in the following tests.
ORAL ESTROGENIC ACTIVITY
The estrogenic activity was determined using immature female rates ovariectomized at 21 days of age. Treatment was by oral administration for 4 days, beginning on the day of ovariectomy. Animals were autopsied on the day following the last administration of test compound. Vaginal smears were obtained from animals that had open vaginas at the time of autopsy. The endpoints for comparison with a standard estrogen will be the increase in uterin weight and cornification of vaginal smears. (The test compounds were diluted with a 0.5% Carboxymethyl cellulose suspension.)
ORAL POSTOCOITAL ACTIVITY
Oral postcoital activity was determined using adult cycling female rats, obtained from the Holtzman Rat Company, were selected in the proestrous phase of the cyle. Treatment began on the day of proestrus. Each female was caged overnight with two adult males. The find of sperm in the vaginal smear the following morning was used as evidence of insemination. Treatment was continued for a total of 8 days. The rats were sacrificed on the day following the last treatment, and the number of implantation sites and the number of corpora lutea were counted. The test material was administered parenterally (sc or im or orally by intubation).
SUBCUTANEOUS ESTROGENIC ACTIVITY
Immature, 18-day-old rats are assigned randomly to groups of 5 to 10. Treatment by S.C. injection is started on the day the animals arrive and continues once daily for 4 days. On day 5, vaginal smears are obtained, and uteri--carefully dissected between precise areas between the cervix and the oviduct--are stripped of fat and connective tissue and then weighed on a torsion balance. Fluid in uteri is expressed before weighing. Body weights of rats are recorded on the first day and at autopsy.
Comparison of the semilog dose-response curves of 3 to 4 dose levels of an active test compound with those of compounds of known activity (e.g., estrone administered s.c. or ethinyl estradiol given orally) helps determine whether the estrogen is strong, weak, or impeded and may give some indication of potential antiestrogenic activity.
Contraceptive activity test
The activities so determined are listed in Table 2.
              TABLE 2                                                     
______________________________________                                    
                                Estrogenic Acti-                          
                                vity relative                             
        Estrogenic  Contraceptive                                         
                                to Estradiol                              
Compound                                                                  
        Activity (Oral)                                                   
                    Activity (Oral)                                       
                                (Subcutaneous)                            
______________________________________                                    
Standard                                                                  
        100         100         1000                                      
(Ethynyl                                                                  
Estradiol)                                                                
1.                               34                                       
3.      531         5000                                                  
4.      228         4000                                                  
5.      780                                                               
6.      696         4000        7472                                      
7.      400                                                               
8.      1400                                                              
9.      8                                                                 
10.     5                                                                 
11.                              7-12                                     
12.     445         400                                                   
13.     1                                                                 
14.                             26-69                                     
15.     60                                                                
17.     300         >100                                                  
18.     22          200                                                   
19.     37          >2000                                                 
20.                             40                                        
______________________________________
As can be seen from these results, several of the compounds provide estrogenic activities that are as much as 7, 14 and even 26 times as great as ethynyl estradiol, itself one of the most potent estrogens. Similarly, compounds of this invention can exhibit postcoital infertility activity 40 and 50 times as high as ethynyl estradiol. This points to significantly lowered use levels which could in turn reduce side effects.
The compounds of this invention can be administered to humans or other mammals by any of the accepted modes of administration for steroidal agents. These methods include oral, parenteral, suppositories, topical and the like. The compounds can be administered alone or as part of a combination product--such as with a progestin or the like.
Depending on the intended mode of administration, the compositions used may be in the form of solid, semisolid or liquid dosage forms, such as, for example, injectables, tablets, suppositories, pills, capsules, powders, liquids, suspensions, or the like, preferably in unit dosage forms suitable for single administration of precise dosages. The compositions will include a conventional pharmaceutical carrier or excipient and an active compound of the invention and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, etc. For oral administration, a pharmaceutically acceptable non-toxic composition is formed by the incorporation of any of the normally employed excipients, such as, for example pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, sucrose, magnesium, carbonate, and the like. Such compositions take the form of solutions, suspensions, tablets, pills, capsules, powders, sustained release formulations and the like.
The compounds of the invention as defined above may be formulated as suppositories using, for example, polyalkylene glycols, for example, propylene glycol, as the carrier.
Liquid pharmaceutically administerable compositions particularly for parenteral administration (generally characterized by injection--subcutaneously, intramuscularly or intravenously) can be prepared by dissolving, dispersing, etc. a compound of the invention and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, etc. Actual method of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 15th Edition, 1975. The composition of formulation to be administered will, in any event, contain a quantity of the active compounds(s) adequate to achieve the desired estrogenic or contraceptive effect in the subject being treated.
The amount of active compound administered will, of course, be dependent on the activity of the compound, the effect desired and the view of the attending physician. As guidelines, conventional oral estradiol pills and tablets may contain from 0.5 to about 2 mg of active material, while a dose of injectable estradiol may be from about 1 to about 10 mg of the active material. Oral ethynyl estradiol tablets usually contain in the range of from 0.01 to 1 mg of the active material. Oral contraceptives employing ethynyl estradiol generally contain from about 0.02 to about 0.1 mg of ethynyl estradiol. In view of the activities demonstrated with compounds of this invention one could obtain desired responses with from as little as 0.0002 mg of active material to as much as 5 or 10 mg. The following nonlimiting representative product formulations further illustrate the use of the present materials in pharmaceutical composition.
FORMULATION A Estrogenic Tablet 
______________________________________                                    
Ingredients       Quantity, g                                             
______________________________________                                    
Compound of Example 8                                                     
                  0.005                                                   
Constarch         40                                                      
Lactose           58                                                      
Magnesium stearate                                                        
                  2                                                       
______________________________________
The above materials are blended in a lab scale ν-blender and hand pressed into 100 mg tablets each of which administers a unit dose of 0.005 mg of the estrogenic compound of example 8.
FORMULATION B Estrogenic Capsule 
______________________________________                                    
Ingredients       Quantity, g                                             
______________________________________                                    
Compound of Example 5                                                     
                  0.05                                                    
Lactose (spray dried)                                                     
                  198                                                     
Magnesium stearate                                                        
                  2                                                       
______________________________________
The above materials are mixed to give a free flowing powder. Hard shell gelatin capsules are filled with 200 mg of the above mixture to achieve a unit dosage form for 0.05 mg estrogen therapy.
FORMULATION C Estrogenic Vaginal Cream
A vaginal cream is formulated by admixing 0.15 mg/g of final product of Example 12 in a cream base made up of glycerin, mineral oil, glycerol monostearate, polyethylene glycol ether complex of fatty acids, cetyl alcohol, lanolin. When one cc of this product is administered an estrogenic response is achieved.
FORMULATION D Androgen-Estrogen Tablets 
______________________________________                                    
Ingredients        Quantity, g                                            
______________________________________                                    
Methyl testosterone                                                       
                   1.25                                                   
Compound 6 of Example 6                                                   
                   0.10                                                   
Constarch          75                                                     
Lactose            168.75                                                 
Magnesium stearate 5.0                                                    
______________________________________
The above materials are intimately mixed and formed into 1000 250 mg tablets each of which delivers 1.25 mg of androgen and 0.10 mg of estrogen.
FORMULATION E Oral Contraceptive Tablet 
______________________________________                                    
Ingredients        Quantity, g                                            
______________________________________                                    
Compound 6 of Example 6                                                   
                   0.001                                                  
Norgestrol progestogen                                                    
                   5.0                                                    
Lactose            95                                                     
Cornstarch         145                                                    
Magnesium stearate 5                                                      
______________________________________
The above ingredients are mixed and formed into 250 mg tablets which when administered to a female exhibit contraceptive activity.
FORMULATION F Oral Contraceptive 
______________________________________                                    
Ingredient         Quantity, g                                            
______________________________________                                    
Compound 3 of Example 3                                                   
                   0.01       g                                           
Lactose            100                                                    
Cornstarch         145                                                    
Magnesium stearate 5                                                      
______________________________________
The above ingredients are mixed and formed into 250 mg tablets which when administered to a female human exhibit postcoital contraceptive activity.
FORMULATION G Topical Formulation 
______________________________________                                    
Ingredients           Quantity, g                                         
______________________________________                                    
Active compound 12 of Example 12                                          
                      0.002                                               
Span 60               2                                                   
Tween 60              2                                                   
Mineral Oil           5                                                   
Petrolatum            10                                                  
Methyl paraben        0.15                                                
Propyl paraben        0.05                                                
BHA (butylated hydroxy anisole)                                           
                      0.01                                                
Water q.s.            100                                                 
______________________________________
All of the above ingredients, except water, are combined and heated to 60° C. with stirring. A sufficient quantity of water at 60° C. is then added with vigorous stirring to emulsify the ingredients, and water then added q.s. 100 g.

Claims (36)

What is claimed is:
1. A compound of the formula ##STR7## wherein R1 is selected from the group consisting of hydrogen, lower alkyl, cycloalkyl and lower acyl; and
R3 is lower alkoxyl.
2. The compound of claim 1 wherein R1 is acetyl.
3. A compound of the formula ##STR8## wherein R1 is selected from the group consisting of hydrogen, lower alkyl, cycloalkyl and lower acyl; and
R5 is selected from the group consisting of lower alkyl and hydrogen.
4. The compound of claim 3 having the formula ##STR9## wherein R1 is selected from the group consisting of hydrogen, lower alkyl, cycloalkyl and lower acyl.
5. The compound of claim 4 having the formula ##STR10##
6. The compound of claim 3 wherein R5 is a lower alkyl.
7. The compound of claim 6 having the formula ##STR11##
8. A compound of the formula ##STR12## wherein R1 is selected from the group consisting of hydrogen, lower alkyl, cycloalkyl and lower acyl; and
R5 is a lower alkyl.
9. A compound of the formula ##STR13## wherein R1 is a selected from the group consisting of hydrogen, lower alkyl, cycloalkyl and lower acyl;
R3 is selected from the group consisting of hydrogen, hydroxyl and lower alkoxy;
R4 is a pair of substituents the α one of which being selected from hydrogen and lower alkynyl, and the β one of which being selected from alkanoic acid esters, lower alkyl and hydroxyl; and
R5 is selected from the group consisting of lower alkyl and hydrogen, subject to the proviso that if R4 is an α .[.hydroxyl.]. .Iadd.hydrogen .Iaddend.and a β alkanoic acid ester or .[.hydrogen,.]. .Iadd.hydroxyl .Iaddend.then R5 must be a lower alkyl.
10. A compound of the formula ##STR14## wherein R1 is selected from the group consisting of hydrogen, lower alkyl, cycloalkyl, and lower acyl;
R3 is selected from the group consisting of hydrogen, hydroxyl, and lower alkoxy; and
R5 is lower alkyl.
11. The compound of claim 10 having the formula ##STR15## wherein R1 is selected from the group consisting of hydrogen, lower alkyl, cycloalkyl, and lower acyl; and
R5 is a lower alkyl.
12. The compound of claim 11 having the formula ##STR16##
13. A compound of claim 9 of the formula ##STR17## wherein R1 is selected from the group consisting of hydrogen, lower alkyl, cycloalkyl and lower acyl;
R4 is a pair of substituents, the α one of which being a lower alkynyl and the β one of the which being a hydroxyl; and
R5 is a lower alkyl.
14. A compound of claim 13 of the formula ##STR18## wherein R4 is a pair of substitutents the α one of which being a lower alkynyl and the β one of which being a hydroxyl.
15. The compound of claim 14 having the formula ##STR19##
16. The compound of claim 9 wherein R4 is an α hydrogen and a α lower alkyl and R3 is hydroxyl.
17. The compound of claim 16 wherein R5 is a lower alkyl.
18. The compound of claim 16 wherein R5 is hydrogen.
19. The compound of claim 18 having the formula ##STR20##
20. The compound of claim 9 where in R4 is an α alkynyl and a β lower alkanoic acid ester.
21. The compound of claim 16 having the formula ##STR21## wherein R1 is selected from the group consisting of hydrogen, lower alkyl, cycloalkyl and lower acyl.
22. The compound of claim 21 having the formula ##STR22##
23. A pharmaceutical composition useful for producing an estrogenic effect in a female mammal which comprises an effective estrogenic amount of a compound of claim 3 in admixture with a pharmaceutically acceptable excipient.
24. A pharmaceutical composition useful for producing a contraceptive effect in a female mammal which comprises an effective contraceptive amount of a compound of claim 3 in admixture with a pharmaceutically acceptable excipient.
25. A method of treating a female mammal to achieve an estrogenic effect therein which comprises administering to said mammal an effective estrogenic amount of the pharmaceutical composition of claim 23.
26. A method of treating a female mammal to achieve a contraceptive effect therein which comprises administering to said mammal an effective contraceptive amount of the pharmaceutical composition of claim 24.
27. A pharmaceutical composition useful for producing an estrogenic effect in a female mammal which comprises an effective estrogenic amount of a compound of claim 10 in admixture with a pharmaceutically acceptable excipient.
28. A pharmaceutical composition useful for producing a contraceptive effect in a female mammal which comprises an effective contraceptive amount of a compound of claim 10 in admixture with a pharmaceutically acceptable excipient.
29. A pharmaceutical composition useful for producing an estrogenic effect in a female mammal which comprises an effective estrogenic amount of a compound of claim 12 in admixture with a pharmaceutically acceptable excipient.
30. A pharmaceutical composition useful for producing a contraceptive effect in a female mammal which comprises an effective contraceptive amount of a compound of claim 12 in admixture with a pharmaceutically acceptable excipient.
31. A pharmaceutical composition useful for producing an estrogenic effect in a female mammal which comprises an effective estrogenic amount of a compound of claim 13 in admixture with a pharmaceutically acceptable excipient.
32. A pharmaceutical composition useful for producing a contraceptive effect in a female mammal which comprises an effective contraceptive amount of a compound of claim 13 in admixture with a pharmaceutically acceptable excipient.
33. A pharmaceutical composition useful for producing an estrogenic effect in a female mammal which comprises an effective estrogenic amount of a compound of claim 15 in admixture with a pharmaceutically acceptable excipient.
34. A pharmaceutical composition useful for producing a contraceptive effect in a female mammal which comprises an effective contraceptive amount of a compound of claim 15 in admixture with a pharmaceutically acceptable excipient. .Iadd.
35. A compound of the formula ##STR23## wherein R1 is selected from the group consisting of hydrogen, lower alkyl, cycloalkyl and lower acyl;
R3 is selected from the group consisting of hydrogen, hydroxyl and lower alkoxy;
R4 a pair of substituents the alpha one of which being selected from hydrogen and lower alkynyl, and the beta one of which being selected from alkanoic acid ester lower alkyl and hydroxyl; and
R5 is selected from the group consisting of lower alkyl and hydrogen, subject to the proviso that if R3 is a hydroxyl and R4 is an alpha hydrogen and a beta alkanoic acid ester or hydrogen, then R5 must be a lower alkyl. .Iaddend. .Iadd.
36. The compound of claim 35 wherein
R1 is hydrogen,
R3 is hydrogen,
R4 is a pair of substituents the alpha one of which is hydrogen and the beta one of which is hydroxyl, and
R5 is hydrogen. .Iaddend.
US07/434,849 1985-06-25 1989-11-09 9 alpha, 11 beta-substituted and 11 beta-substituted estranes Expired - Lifetime USRE34136E (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US07/434,849 USRE34136E (en) 1985-06-25 1989-11-09 9 alpha, 11 beta-substituted and 11 beta-substituted estranes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/748,489 US4705783A (en) 1985-06-25 1985-06-25 9α, 11β-substituted and 11β-substituted estranes
US07/434,849 USRE34136E (en) 1985-06-25 1989-11-09 9 alpha, 11 beta-substituted and 11 beta-substituted estranes

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US06/748,489 Reissue US4705783A (en) 1985-06-25 1985-06-25 9α, 11β-substituted and 11β-substituted estranes

Publications (1)

Publication Number Publication Date
USRE34136E true USRE34136E (en) 1992-12-01

Family

ID=25009663

Family Applications (3)

Application Number Title Priority Date Filing Date
US06/748,489 Ceased US4705783A (en) 1985-06-25 1985-06-25 9α, 11β-substituted and 11β-substituted estranes
US07/088,802 Expired - Fee Related US4859370A (en) 1985-06-25 1987-08-24 9 alpha, 11 beta-substituted and 11 beta-substituted estranes
US07/434,849 Expired - Lifetime USRE34136E (en) 1985-06-25 1989-11-09 9 alpha, 11 beta-substituted and 11 beta-substituted estranes

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US06/748,489 Ceased US4705783A (en) 1985-06-25 1985-06-25 9α, 11β-substituted and 11β-substituted estranes
US07/088,802 Expired - Fee Related US4859370A (en) 1985-06-25 1987-08-24 9 alpha, 11 beta-substituted and 11 beta-substituted estranes

Country Status (9)

Country Link
US (3) US4705783A (en)
EP (1) EP0227813B1 (en)
JP (1) JPH0816117B2 (en)
AT (1) ATE68001T1 (en)
DE (1) DE3681786D1 (en)
DK (1) DK98087A (en)
FI (1) FI88509C (en)
NO (1) NO870759L (en)
WO (1) WO1987000175A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554603A (en) * 1993-09-17 1996-09-10 The United States Of America As Represented By The Department Of Health And Human Services Orally active derivatives of 1,3,5(10)-estratriene

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960010793B1 (en) * 1986-10-10 1996-08-08 루쎌 위클라프 소시에떼 아노님 9-alpha-hydroxy steroids, process for their preparation and process for the preparation of the corresponding 9(11)-dehydro-derivatives
US5137882A (en) * 1990-06-11 1992-08-11 Holt Dennis A Steroidal 3-acetic acid derivatives as 5-alpha-reductase inhibitors
US6551611B2 (en) 1995-09-28 2003-04-22 Schering Aktiengesellschaft Hormone replacement therapy method
US6083528A (en) * 1995-09-28 2000-07-04 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
US5922349A (en) * 1995-09-28 1999-07-13 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
US6503896B1 (en) 1997-12-24 2003-01-07 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6548491B2 (en) 1997-12-24 2003-04-15 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
DE19906159A1 (en) * 1999-02-09 2000-08-10 Schering Ag 16-hydroxyestratrienes as selectively active estrogens
AU1855201A (en) * 1999-11-02 2001-05-14 Schering Aktiengesellschaft 18-nor-steroids as selectively active estrogens
US20050282791A1 (en) * 1999-11-02 2005-12-22 Alexander Hillisch 18-nor steroids as selectively active estrogens
US6958327B1 (en) 1999-11-02 2005-10-25 Schering, Ag 18 Norsteroids as selectively active estrogens
US7041839B2 (en) * 2000-06-22 2006-05-09 Northeastern University Steroidal antiestrogens and antiandrogens and uses thereof
US8173628B2 (en) * 2000-06-22 2012-05-08 Northeastern University Steroidal antiestrogens and antiandrogens and uses thereof
WO2002022645A2 (en) * 2000-09-14 2002-03-21 Accelerated Pharmaceuticals, Inc. Method of making 7alpha-methyl-11beta-methoxy estradiol and related compounds with estrogenic activity
DE10233723A1 (en) * 2002-07-24 2004-02-12 Schering Ag Preparation of 7 alpha-substituted 11 alpha-hydroxy-steroids, useful as precursors for new androgenic 7 alpha,17 alpha-substituted 11 beta-halo-steroids, by microbiological conversion of 7 alpha-substituted steroids
CA2518506A1 (en) * 2003-03-13 2004-11-18 Nitromed, Inc. Nitrosated and nitrosylated compounds, compositions and methods of use

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1453216A (en) * 1963-06-12 1966-06-03 Roussel Uclaf New estradiol derivatives and method of preparation
FR6854M (en) * 1967-12-15 1969-04-08
GB1151404A (en) * 1966-06-07 1969-05-07 Roussel Uclaf Novel Gona-1,3,5(10)-Trienes, Processes for their Preparation, and Compositions incorporating them
US3755574A (en) * 1971-01-21 1973-08-28 Roussel Uclaf Estrogenic compositions comprising 11beta-alkoxy-gona-1,3,5(10)-trienes
US3980681A (en) * 1969-11-21 1976-09-14 Peter Job Sykes Process for the preparation of 11-β-nitro-oxysteroids
DE2752695A1 (en) * 1976-11-26 1978-06-01 Akzo Nv STEROIDESTER

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1074493A (en) * 1963-06-12 1967-07-05 Roussel Uclaf Novel estrane derivatives and processes for preparing them
US3411567A (en) * 1966-06-13 1968-11-19 United Eng Foundry Co Mold supporting structure for casting machine
US3906096A (en) * 1971-11-23 1975-09-16 Roussel Uclaf Novel 11{62 -alkoxy steroids
US3755301A (en) * 1972-06-23 1973-08-28 Searle & Co Manufacture of 11-alkyl steroids
NL7405626A (en) * 1974-04-26 1975-10-28 Akzo Nv NEW 11-SUBSTITUTED STEROIDS OF THE OESTRAAN SERIES.
DE3248434A1 (en) * 1982-12-23 1984-06-28 Schering AG, 1000 Berlin und 4709 Bergkamen METHOD FOR PRODUCING 3.11 (ALPHA) -DIHYDROXY-1,3,5 (10) -ESTRATRINE DERIVATIVES

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1453216A (en) * 1963-06-12 1966-06-03 Roussel Uclaf New estradiol derivatives and method of preparation
GB1151404A (en) * 1966-06-07 1969-05-07 Roussel Uclaf Novel Gona-1,3,5(10)-Trienes, Processes for their Preparation, and Compositions incorporating them
FR6854M (en) * 1967-12-15 1969-04-08
US3980681A (en) * 1969-11-21 1976-09-14 Peter Job Sykes Process for the preparation of 11-β-nitro-oxysteroids
US3755574A (en) * 1971-01-21 1973-08-28 Roussel Uclaf Estrogenic compositions comprising 11beta-alkoxy-gona-1,3,5(10)-trienes
DE2752695A1 (en) * 1976-11-26 1978-06-01 Akzo Nv STEROIDESTER
US4312864A (en) * 1976-11-26 1982-01-26 Akzona Incorporated Branched chain and cycloaliphatic esters of the androstane and destrane series and pharmaceutical compositions containing same

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts, vol. 100, No. 15, Apr. 1984, Li, Zhensu et al., "Synthesis of 11-Substituted (Containing Oxygen Group) Estradiol)," p. 626, Abstract No. 121429p.
Chemical Abstracts, vol. 100, No. 15, Apr. 1984, Li, Zhensu et al., Synthesis of 11 Substituted (Containing Oxygen Group) Estradiol), p. 626, Abstract No. 121429p. *
Chemical Abstracts, vol. 75 (1971) #129995F, Sykes et al.
Chemical Abstracts, vol. 75 (1971) #88842H, Sykes et al.
Chemical Abstracts, vol. 75 (1971) 129995F, Sykes et al. *
Chemical Abstracts, vol. 75 (1971) 88842H, Sykes et al. *
J. P. Raynaud, et al.; Drug Design, vol. VIII, 1979, pp. 178 181. *
J. P. Raynaud, et al.; Drug Design, vol. VIII, 1979, pp. 178-181.
Journal of Medicinal Chemistry, vol. 10, No. 6, Nov. 1967, J. S. Baran, "A Synthesis Of 11beta-Hydroxyestrone And Related 16-and 17-Hydroxyestratrienes", pp. 1188-1190.
Journal of Medicinal Chemistry, vol. 10, No. 6, Nov. 1967, J. S. Baran, A Synthesis Of 11beta Hydroxyestrone And Related 16 and 17 Hydroxyestratrienes , pp. 1188 1190. *
Steroids, vol. 34, No. 4, Oct. 1979, J. Salmon et al., "Reference Compounds For The Study of Moxestrol Metabolism" pp. 381-300.
Steroids, vol. 34, No. 4, Oct. 1979, J. Salmon et al., Reference Compounds For The Study of Moxestrol Metabolism pp. 381 300. *
Tetrahedron Letters, No. 37, pp. 3393 3396 (1971), Sykes et al. *
Tetrahedron Letters, No. 37, pp. 3393-3396 (1971), Sykes et al.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554603A (en) * 1993-09-17 1996-09-10 The United States Of America As Represented By The Department Of Health And Human Services Orally active derivatives of 1,3,5(10)-estratriene

Also Published As

Publication number Publication date
ATE68001T1 (en) 1991-10-15
EP0227813B1 (en) 1991-10-02
DK98087D0 (en) 1987-02-25
DK98087A (en) 1987-02-25
DE3681786D1 (en) 1991-11-07
JPS63500101A (en) 1988-01-14
NO870759D0 (en) 1987-02-24
EP0227813A1 (en) 1987-07-08
US4705783A (en) 1987-11-10
NO870759L (en) 1987-02-24
FI88509B (en) 1993-02-15
WO1987000175A1 (en) 1987-01-15
FI870808A (en) 1987-02-25
FI88509C (en) 1993-05-25
JPH0816117B2 (en) 1996-02-21
FI870808A0 (en) 1987-02-25
US4859370A (en) 1989-08-22

Similar Documents

Publication Publication Date Title
USRE34136E (en) 9 alpha, 11 beta-substituted and 11 beta-substituted estranes
EP0485392B1 (en) Androgen derivatives for use in the inhibition of sex steroid activity
RU2166509C2 (en) Derivatives of 19-norpregnene, pharmaceutical composition, compounds
US4512986A (en) Progrestationally active steroids
US5116865A (en) 15,16-seco-19-nor progestins
HU203764B (en) Process for producing 11-beta-4,9,15-estratiene derivatives and pharamceutical compositions containing them
EP0145493B1 (en) 11-difluoromethyl and 11-fluoromethylene steroids
US3159543A (en) 3-cyclopentyl and cyclopentenyl ethers of estrone and derivatives thereof
US20100029603A1 (en) 16alpha-methyl or ethyl substituted estrogens
US3928398A (en) Derivatives of 7{60 -methylestr-4-en-3{60 ,17{62 -diol
EP0318490B1 (en) 14,17-g(b)-ethano-14-g(b)-estratrienes, process for their manufacture and pharmaceutical preparations containing these
US3890356A (en) 7-Alkyl-{66 {hu 3,5{b -steroids
Crabbe et al. Chemical synthesis and bioassay of anordrin and dinordrin I and II
US4073899A (en) Method of terminating pregnancy
US4557867A (en) 11β-Difluoromethyl and (E)- and (Z)-11-fluoromethylene steriods
RU2099347C1 (en) 17α-ACETOXY-3β-BUTANOYLHYDROXY-6-METHYLPREGNA-4,6-DIENE-20-ONE SHOWING GESTAGENIC ACTIVITY
US3717663A (en) 9-alpha-methyl steroids
US3629234A (en) Estradiol-17beta-rhamnosides
AU708135C (en) New 19-nor-pregnene derivatives
US3501510A (en) Estriol derivatives
US3655652A (en) Aromatically-unsaturated 9alpha-methyl steroids

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12